Online inquiry

IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5420MR)

This product GTTS-WQ5420MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD74 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001025158.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 972
UniProt ID P04233
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ5420MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2275MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALXN1007
GTTS-WQ13885MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-2176
GTTS-WQ8205MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA hLIV22
GTTS-WQ4055MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BI 655130
GTTS-WQ6669MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ7987MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GX-H9
GTTS-WQ8672MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ5874MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CIFN
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW